From Pulse 2.0 · Amit Chowdhry · · 40s
Coherence Neuro Raises $45M Series A
Coherence Neuro secures $45M Series A to build real-time cancer treatment systems using electrical biomarkers.
In brief
Coherence Neuro secures $45M Series A to build real-time cancer treatment systems using electrical biomarkers. Coherence Neuro raised $45 million to develop adaptive cancer treatment systems that monitor and respond to tumors via real-time electrical signals. Originally reported by Pulse 2.0.
Funding Round
Coherence Neuro raised $45 million Series A co-led by Founders Fund and The OpenAI Startup Fund.
New Investors
New investors include Lux Capital, 8VC, Timeless, Olive Capital, Ahren, and Neuralink experts.
Technology Approach
Coherence uses electrical biomarkers to track tumor growth via neural activity in preclinical models.
Next Steps
Coherence plans first chronic human trial in glioblastoma and seeks FDA Breakthrough Device designation.
In short
Coherence Neuro raised $45 million to develop adaptive cancer treatment systems that monitor and respond to tumors via real-time electrical signals.
